GTC Biotherapeutics (fka GTCB)

[DewDiligence]

What is GTC’s Business Model?


The simplified version:

“We are strongly of the opinion that,
for any therapeutic protein, we can
be the low-cost provider.”

—CEO Geoffrey Cox (from the Nov 2006 Lazard webcast)


The unabridged version:

“We see ourselves primarily as a production company in the follow-on biologics and second generation area with established pre-clinical development capabilities. We anticipate the commercialization will primarily be the responsibility of our partners… We are also able to provide a strong intellectual property position that is independent of the cell culture process patents including the patents commonly referred to as Cabilly that could otherwise inhibit development in this area.”

—CEO Geoffrey Cox (from GTC’s 1Q07 conference call)